Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Therapy for ctDNA+ Resectable CRLM
NCT05797077Phase 3Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Feb 2023
- Primary completion
- Feb 2029
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in colorectal cancer (CRC), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Started Feb 2023; status: recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05797077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797077.